BioNTech SE (22UA.F)

EUR 107.0

(-2.28%)

Operating Expenses Summary of BioNTech SE

BioNTech SE's latest annual operating expenses in 2023 was 2.52 Billion EUR , up 1603.46% from previous year.
BioNTech SE's latest quarterly operating expenses in 2024 Q2 was 772.28 Million EUR , up 19.94% from previous quarter.
BioNTech SE reported a annual operating expenses of 135.9 Million EUR in annual operating expenses 2022, down -32.08% from previous year.
BioNTech SE reported a annual operating expenses of 200.1 Million EUR in annual operating expenses 2021, up 243.32% from previous year.
BioNTech SE reported a quarterly operating expenses of 643.86 Million EUR for 2024 Q1, down -8.27% from previous quarter.
BioNTech SE reported a quarterly operating expenses of 194.7 Million EUR for 2023 Q2, up 65.0% from previous quarter.

Annual Operating Expenses Chart of BioNTech SE (2023 - 2017)

Historical Annual Operating Expenses of BioNTech SE (2023 - 2017)

Year	Operating Expenses	Operating Expenses Growth
2023	2.52 Billion EUR	1603.46%
2022	135.9 Million EUR	-32.08%
2021	200.1 Million EUR	243.32%
2020	-139.62 Million EUR	-401.69%
2019	46.28 Million EUR	87.38%
2018	24.69 Million EUR	-11.98%
2017	28.06 Million EUR	0.0%

Year	Operating Expenses	Operating Expenses Growth
2024 Q2	772.28 Million EUR	19.94%
2024 Q1	643.86 Million EUR	-8.27%
2023 Q2	194.7 Million EUR	65.0%
2023 Q4	701.9 Million EUR	356.67%
2023 FY	2.31 Billion EUR	1603.46%
2023 Q3	153.7 Million EUR	-21.06%
2023 Q1	118 Million EUR	-59.6%
2022 Q4	292.1 Million EUR	100.76%
2022 Q2	110.3 Million EUR	10.85%
2022 Q1	99.5 Million EUR	-5.69%
2022 FY	135.9 Million EUR	-32.08%
2022 Q3	145.5 Million EUR	31.91%
2021 Q3	57.4 Million EUR	-3.69%
2021 Q1	193.8 Million EUR	202.14%
2021 Q2	59.6 Million EUR	-69.25%
2021 FY	200.1 Million EUR	243.32%
2021 Q4	105.5 Million EUR	83.8%
2020 FY	-139.62 Million EUR	-401.69%
2020 Q4	-189.74 Million EUR	-1083.42%
2020 Q3	19.29 Million EUR	-11.71%
2020 Q2	21.85 Million EUR	36.79%
2020 Q1	15.97 Million EUR	44.34%
2019 Q1	9.54 Million EUR	-3.64%
2019 Q3	10.91 Million EUR	-26.09%
2019 Q4	11.06 Million EUR	1.45%
2019 FY	46.28 Million EUR	87.38%
2019 Q2	14.76 Million EUR	54.68%
2018 Q2	30.27 Million EUR	0.0%
2018 Q1	30.27 Million EUR	0.0%
2018 Q3	6.45 Million EUR	-78.67%
2018 Q4	9.9 Million EUR	53.38%
2018 FY	24.69 Million EUR	-11.98%
2017 FY	28.06 Million EUR	0.0%

Peer Operating Expenses Comparison of BioNTech SE

Name	Operating Expenses	Operating Expenses Difference
CureVac N.V.	211.75 Million EUR	-1094.216%
Biotest Aktiengesellschaft	136.8 Million EUR	-1748.538%
Biotest Aktiengesellschaft	136.8 Million EUR	-1748.538%
BRAIN Biotech AG	24.94 Million EUR	-10039.128%
Formycon AG	23.73 Million EUR	-10555.206%
Heidelberg Pharma AG	27.81 Million EUR	-8991.209%
Medigene AG	20.54 Million EUR	-12211.587%